Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
분석일: 2026-05-13다음 업데이트: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
주가
$381.75
▲ +250.57 (+65.64%)
공정 가치
$632
$411–$854
등급
적극 매수
confidence 77/100
상승 여력
+65.6%
upside to fair value
안전 마진
$537.47
MoS level · 15%
시가총액
$82.9B
P/E fwd 13.1
영어 원본으로 대체KO
번역하는 동안 영어 원본을 표시 중
이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

§1 개요

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 베어 케이스

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

이 논제가 무너지는 경로

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
모니터링할 조기 경보 신호
지표현재트리거 임계값
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 재무 이력

손익계산서 — 최근 6기
항목T−0T−1T−2T−3T−4CAGR
기간2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
매출$156.60B$171.34B$176.81B$199.13B+6.2%
매출총이익
영업이익
순이익$5.89B$5.99B$5.98B$5.66B-1.0%
EPS (희석)$24.81$25.22$25.68$25.21+0.4%
EBITDA
R&D
판관비$15.91B$17.69B+2.7%

품질 점수

OCF / 순이익
0.76×
>1은 이익의 질이 높음을 의미
회계 품질 게이트
Fail
섹터 조정 게이트
ROIC
8.4%
투하자본수익률
섹션 3

Numbers analysis

현금 흐름

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

자본 배분

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

개인 구독자 — §4부터11개 섹션 더

전체 분석 읽기 — 11개 섹션 더.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

모든 커버 종목에 대한 전체 보고서
24개월 등급 아카이브
관심 목록 브리핑 + 등급 변경 알림
모든 언어로 PDF + DOCX 내보내기
무료 체험 시작
언제든지 취소 가능.
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder